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Abstract
The alkylation of amino groups of the mineralocorticoid receptor (MR) with pyridoxal 5P-phosphate or 2,4,6-
trinitrobenzenesulphonate (TNBS) under controlled conditions modifies only one lysyl residue, which accounts for a 70%
inhibition of steroid binding capacity. The Kd of aldosterone for MR is not affected by the treatment, but the total number of
binding sites is greatly decreased. The modified receptor is capable of dynamically conserving its association with the hsp90-
based heterocomplex. Importantly, the binding of natural agonists protects the hormone binding capacity of the MR from
the inactivating action of alkylating agents. In contrast, antagonistic steroids are totally incapable of providing such
protection. Like the antagonistic ligands, and despite its potent mineralocorticoid biological effect, the sole MR specific
synthetic agonist known to date, 11,19-oxidoprogesterone (11-OP), shows no protective effect upon treatment of the MR
with pyridoxal 5P-phosphate or TNBS. Limited digestion of the MR with K-chymotrypsin generates a 34 kDa fragment,
which becomes totally resistant to digestion upon binding of natural agonists, but not upon binding of antagonists.
Interestingly, the synthetic 21-deoxypregnanesteroid 11-OP exhibits an intermediate pattern of proteolytic degradation,
suggesting that the conformational change generated in the MR is not equivalent to that induced by antagonists or natural
agonists. We conclude that in the first steps of activation, the MR changes its conformation upon binding of the ligand.
However, the nature of this conformational change depends on the nature of the ligand. The experimental evidence shown in
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this work suggests that a single lysyl group can determine the hormone specificity of the MR. ß 2002 Elsevier Science B.V.
All rights reserved.
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1. Introduction
The steroid hormone receptors belong to a nuclear
receptor superfamily of ligand-induced transcription
factors which share a common set of three main
domains [1]. A central domain binds to hormone
response elements in the DNA of target cells, an
N-terminal region mediates transactivation, and the
C-terminal domain binds the ligand.
Most of the members of the steroid receptor super-
family exist in a heterocomplex with the 90 kDa heat
shock protein (hsp90)-based chaperone system [2].
This association stabilises steroid receptors in the
hormone binding form and prevents their transcrip-
tional activity. The binding of hormone to the ste-
roid receptor triggers a series of events before the
receptor recruits other transcription factors. It is
thought that when the steroid binds to the receptor,
it generates a conformational change that would lead
to the dissociation of the hsp90 heterocomplex (re-
ferred to as transformation), followed by receptor
dephosphorylation, dimerisation and, for cytoplas-
mic receptors, translocation into the nucleus. The
transformed receptor interacts with speci¢c DNA se-
quences, undergoes hyperphosphorylation and re-
cruits co-activators or co-repressors to regulate the
¢nal biological response. Indeed, the actual temporal
sequence of this cascade of events is almost un-
known.
Nevertheless, the experimental evidence suggests
that the receptor ¢rst undergoes dephosphorylation
[3] and then hyperphosphorylation [4] during the
hormone-dependent activation process. It has also
been shown that the dissociation of hsp90 upon ste-
roid binding is not necessarily the ¢rst step in the
glucocorticoid receptor (GR) signalling pathway [5].
In e¡ect, recent evidence shows that hsp90 may be
required for GR tra⁄cking on cytoskeletal tracts
[6,7] in a process where cytoplasmic dynein may act
as a motor protein for the retrograde movement of
the GR [8,9].
The primary event that triggers all these molecular
events is the hormone binding to the receptor. Under
normal physiological conditions, aldosterone
(ALDO) is the endogenous ligand responsible for
MR activation in epithelia and vascular smooth
muscle cells. However, in non-epithelial cells such
as cardiomyocytes and neurones, the physiologic pre-
dominant occupant appears to be cortisol, commonly
but not unequivocally as an antagonist. The activa-
tion of the mineralocorticoid receptor (MR) in kid-
ney leads to the critical regulation of the internal
medium by sodium and water retention, and potas-
sium and proton elimination.
The structures of the MR and the GR are very
similar [1]. Since their DNA binding domains are
94% homologous, the cross-talk between trans-
formed receptors with their respective hormone re-
sponse elements is not a surprise. Moreover, the hor-
mone binding domains are 57% homologous, so
cross-reaction between glucocorticoid and mineralo-
corticoid ligands also occurs. In fact, glucocorticoids
would also activate the MR if the protective action
of the enzyme 11L-hydroxysteroid dehydrogenase
would not inactivate glucocorticoids to their 11-
keto derivative [10]. Interestingly, it has also been
described that certain physiological metabolites of
progesterone (PROG) produced during pregnancy
inhibit the activity of the enzyme allowing glucocor-
ticoids to acquire mineralocorticoid properties by ac-
tivation of the renal MR [11].
Despite the high similarity between the GR and
the MR, and the overwhelming number of studies
performed with the former receptor, at the present
time our knowledge about the properties of the MR
is very limited. Like the GR, the MR is mainly lo-
calised in the cytoplasm in the absence of hormone
and translocates into the nucleus upon steroid bind-
ing [12^14]. The untransformed MR is an oligomeric
complex associated to hsp90 [15^18] and to hsp90
interacting proteins [19]. Like recombinant human
MR (hMR) [20], rat kidney MR exhibits features
of a phosphoprotein, and it appears to require the
activity of a serine-threonine phosphatase to trans-
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locate into the cell nucleus as suggested by the inhib-
itory e¡ect of tautomycin on the nuclear transloca-
tion of ALDO/MR complexes in intact renal tissue
[14,17,21]. This property has also been reported for
the GR [5,22] under in vitro conditions with whole
cells in culture.
Cysteine groups of the MR play an essential role
in steroid binding as evidenced by its extreme sensi-
tivity to a low redox potential milieu in cell-free sys-
tem [18,21,23,24]. According to a recent study, Cys948
is directly involved in contacting the 20-keto group
of the steroid as evidenced by site-directed mutagen-
esis of the hMR [25]. We have recently provided
direct proof that a low redox potential is required
in vivo for the mineralocorticoid e¡ect by inhibition
of ALDO binding to MR after depletion of tissue
glutathione [26]. Thus, the depletion of the most
prevalent intracellular thiol directly correlates with
the abrogation of both steroid binding capacity of
the MR and the mineralocorticoid response.
In a previous work [27], we described that the total
binding of ALDO to MR is inhibited when amino
groups are modi¢ed with alkylating agents. Interest-
ingly, the preincubation of MR with ALDO pro-
tected the receptor from such inhibition. Neverthe-
less, the synthetic 21-deoxypregnane agonist, 11,19-
oxidoprogesterone (11-OP), was incapable of pro-
tecting the MR from such inactivation. In view of
these new and challenging ¢ndings, in this work we
aimed to dissect the mechanism of inactivation of
steroid binding by using selective reagents for lysyl
residues under speci¢c reaction conditions, and we
studied the putative role of an essential lysine on
the steroid binding capacity of native renal MR to
discriminate binding between antagonists, natural ag-





phosphoric acid, and the 125I-conjugated counteranti-
bodies were purchased from NEN Life Science Prod-
ucts (Boston, MA, USA). RU486 (17L-hydroxy-
11L,4-dimethyl-aminophenyl-17K-propynylestra-4,9-
diene-3-one) was a kind gift from Rousell-Uclaf (Ro-
mainville, France). 11-OP and 6-OP (6,19-oxidopro-
gesterone) were synthesised in our laboratory as pre-
viously described [28]. Unlabelled steroids, PLP
(pyridoxal 5P-phosphate) and its derivatives, TNBS
(2,4,6-trinitrobenzenesulphonate), sodium borohy-
dride, dimethyl pimelimidate, inhibitors of proteases,
K-chymotrypsin from bovine pancreas, L-lysine, NK-
acetyl-L-lysine and NO-acetyl-L-lysine and goat anti-
mouse IgG-horseradish peroxidase conjugate were
from Sigma (St. Louis, MO, USA). [32P]PLP was
prepared from pyridoxamine and anhydrous
[32P]orthophosphoric acid as described by Cabant-
chik et al. [29], and the product purity was checked
by thin layer chromatography in propanol:water:
ammonia (6:1:3). The 3G3 monoclonal IgM anti-
body against the hsp90 and the BuGR2 monoclonal
IgG antibody against the GR were purchased from
A⁄nity Bioreagents (Golden, CO, USA). AC88
monoclonal IgG against hsp90 was from StressGen
(Victoria, BC, Canada). The rabbit polyclonal anti-
body generated against the hMR was described
previously [12]. Donkey anti-rabbit IgG-horse-
radish peroxidase was from Pierce (Rockford, IL,
USA).
2.2. Source of MR
Male Sprague^Dawley rats weighing 200 g under-
went adrenalectomy 48 h before the experiments.
Animals were maintained with fresh water and
0.9% NaCl solution ad libitum. Rats were sacri¢ced
by decapitation and perfused through the aortic ar-
tery with more than 100 ml of ice-cold saline solution
until kidneys were blanched. Additional perfusion of
kidneys was performed through the renal artery until
the medulla was completely blanched. Kidney papil-
lae were dissected and minced to ¢ne pieces with a
scalpel blade. The pieces were either homogenised as
described below to obtain ‘kidney cytosol’, or trans-
ferred to culture tubes containing 0.2% collagenase
and 0.2% hyaluronidase in Krebs bu¡er. Collecting
duct cells were isolated as described by Husted et al.
[30] and cultured in a medium based on a 1:1 mix-
ture of DMEM and Ham’s F-12 containing 10%
fetal calf serum, 50 Wg/ml gentamicin, 100 Wg/ml am-
picillin, and 5 Wg/ml amphotericin B. The medium
was replaced daily, and the day before the experi-
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ment the regular fetal calf serum was replaced with
charcoal-stripped fetal calf serum.
2.3. Preparation of cytosol and immunoprecipitation
of MR
Kidney cytosol or collecting duct cell cytosol was
obtained from minced papillae or primary cultures of
duct cells as follows: either renal papillae or duct
cells were homogenised with 1 vol. of PEGM bu¡er
(25 mM phosphate, 10 mM EDTA, 10% glycerol, 20
mM sodium molybdate, 1 mM PMSF, 20 Wg/ml
aprotinin, 30 Wg/ml trypsin^chymotrypsin inhibitor,
20 Wg/ml leupeptin, and 20 Wg/ml pepstatin, at pH
7.4). The homogenates were centrifuged at 67 000Ug
for 30 min at 0‡C and precleared of GR by immu-
noadsorption with BuGR2 antibody precoupled to
protein A-Sepharose as previously described [26].
Then, the MR was partially puri¢ed by adsorption
to hydroxylapatite gel, eluted and concentrated by
ultra¢ltration as described in detail [26,31,32]. The
resulting preparation is referred to as ‘cytosol’ and
was immediately used for the assays. MR was immu-
nopuri¢ed from this cytosol with the anti-MR anti-
body precoupled to protein A-Sepharose (or non-im-
mune rabbit serum), washed three times with ice-cold
PEGM bu¡er containing 0.02% Nonidet P-40 and
twice with the incubation bu¡er required for each
particular experiment.
2.4. Bioassays
The urinary excretion rates for Na and K were
measured in adrenalectomised male rats injected with
the indicated doses of steroid as described [27,31].
Data were analysed by one-way non-parametric AN-
OVA followed by Kruskal^Wallis test.
2.5. Binding assays
The standard ¢nal volume used for binding studies
was 200 Wl. Binding assays were performed with
20 nM [3H]ALDO at 0‡C for 4 h in PEGM
bu¡er supplemented with 2 mM dithiothreitol and
100 nM RU486. Bound steroid was separated from
free by adding 0.25 vol. of a suspension of 4.0%
charcoal/0.4% dextran when cytosol was used, or
by washing the pellets with PEGM bu¡er when the
assay was performed using immunoadsorbed MR.
The non-speci¢c binding was determined with 500-
fold excess of radioinert ALDO and subtracted from
the total.
2.6. MR^hsp90 covalent cross-linking.
The standard cross-linking reaction was carried
out by adding 0.5 ml of 2.0 M triethanolamine at
pH 8.0 to 5 ml of kidney cytosol [16,18]. The MR
was cross-linked to hsp90 with 20 mM dimethyl pi-
melimidate for 30 min at 5‡C. The reaction was
stopped with 0.3 ml of 2 M Tris^HCl bu¡er at pH
8.0. After 15 min on ice, the samples were loaded
onto a Sephadex G-25 minicolumn equilibrated
with homogenisation bu¡er. The MR^hsp90 hetero-
complex was eluted from the column by a short cen-
trifugation for 60 s at 1200 rpm, pooled, and con-
centrated by ultra¢ltration.
2.7. Sucrose gradient ultracentrifugation
We followed a standard procedure for sucrose gra-
dient centrifugation as described previously [18].
Brie£y, renal cytosol obtained in PEG bu¡er
(PEGM bu¡er without molybdate) was ¢rst labelled
with [3H]ALDO for 4 h at 0‡C (with or without an
excess of unlabelled ALDO), and the free steroid was
adsorbed with charcoal/dextran. The resultant
[3H]ALDO/MR complexes were centrifuged for 90
min at 0‡C at 463 000Ug on a 5^20% sucrose gra-
dient. The shift of the hsp90-associated receptor was
achieved by preincubation of the samples with 30 Wg
of 3G3 antibody at 0‡C for 1 h and then ultracentri-
fuged. Fractions of 250 Wl were collected from the
gradient by gravity £ow and the speci¢c binding of
[3H]ALDO was measured. Myoglobin (2.0 S), BSA
(4.6 S), L-amylase (8.9 S), and catalase (11.3 S) were
used as external markers.
2.8. Lysyl residue modi¢cation
Cell duct cytosol or kidney cytosol (V10 mg pro-
tein/ml) in PEGM bu¡er was incubated at 0‡C with
the indicated concentration of PLP or TNBS. Ali-
quots were taken from the reaction mixture at vari-
ous intervals of time and immediately reduced with a
freshly prepared solution of 10 mM sodium borohy-
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dride. Once the reaction was complete, an additional
10 mM NaBH4 was added to the samples and then
placed on ice for 15 min. Reduced proteins were
quickly separated from the excess of reagents in a
minicolumn of Sephadex G-25, concentrated by ul-
tra¢ltration at 4‡C in the dark, and ¢nally incubated
with [3H]ALDO to determine the speci¢c binding
capacity. When alkylated MR was immunopuri¢ed,
the receptor was released from the immune pellet by
treatment with 1% SDS. Under these conditions,
proteins were quantitatively solubilised. Sepharose
pellets were discarded by centrifugation and the
supernatant was used to perform a spectrophotomet-
ric analysis according to Secundo et al. [33] for PLP-
treated samples, or according to Habeeb [34] for
TNBS-treated pellets. Non-immune pellets were
used as blanks of the reaction. We determined the
empirical molar extinction coe⁄cient for each prod-
uct by using a standard curve of L-Lys pretreated
with either PLP or TNBS under the same reaction
conditions as samples.
2.9. Reconstitution of PLP-modi¢ed immunopuri¢ed
MR
The MR from collecting cortical duct cytosol was
immunopuri¢ed as described above, and stripped of
associated proteins by incubation with 0.5 M KCl
for an additional 2 h at 4‡C. The hsp90-free immune
pellet was modi¢ed with 3 mM PLP for 5 min at
0‡C, reduced with NaBH4, and washed ¢ve times
with 1 ml of bu¡er. This hsp90-free modi¢ed MR
was then reconstituted with rabbit reticulocyte lysate
as the source of chaperones in the presence of an
ATP regenerating system [27]. After washing the pel-
lets three times with PEGM bu¡er, a steroid binding
assay was performed using 20 nM [3H]ALDO as
tracer as described above. The MR and hsp90 were
visualised by Western blotting.
2.10. Limited chymotrypsinisation of MR
Cytosol from cortical collecting duct cells was in-
cubated for 4 h at 0‡C with 1 WM steroid. Samples
were then treated with [32P]PLP as described above
and, after the stabilisation of the Schi¡ base, the MR
was immunopuri¢ed in the presence of hormone.
Subsequent steps were always performed in the pres-
ence of 1 WM steroid. After washing out the super-
natant, the immune pellet was resuspended in PEG
bu¡er containing 0.5 M KCl and rotated for an
additional 2 h at 4‡C. The immune pellet was
washed twice with PEG/0.5 M KCl bu¡er, and three
times with phosphate-bu¡ered saline (PBS). Chymo-
trypsin from bovine pancreas in PBS was then
added to the pellet and incubated at 10‡C for 1 h.
The limited digestion of [32P]PLP-labelled MR was
stopped by boiling the samples in SDS-loading bu¡er
for 3 min. The labelled proteolytic fragments were
resolved by SDS^PAGE on a 14% gel and autoradio-
graphed.
3. Results
3.1. Reaction of PLP with cytosolic renal MR
To address the question whether amino residues of
the MR are essential for steroid binding, we treated
partially puri¢ed renal cytosol with PLP and mea-
sured the speci¢c hormone binding capacity in the
chemically modi¢ed preparation. The phosphate
group of PLP is important for the initial interaction
of the inhibitor with the target protein, whereas the
formyl moiety on C4 is required for the formation of
a covalent imine or Schi¡ base with a primary amino
group. Since the initial imine bond formed by PLP
with the O-amino group of lysine is hydrolysed in
aqueous solution, the primary reaction with PLP
was followed by reduction to the secondary amine
with NaBH4. This reaction also serves to inactivate
any unreacted PLP by reduction of its aldehyde
group. Inasmuch as the reagent is in excess with
respect to the number of reactive lysyl groups, the
reaction should follow pseudo-¢rst order kinetics ac-






MRC ÿ PLP 1
where MRS-PLP represents the initial hydrolysable
imine formed by reaction of amino groups in the
receptor and the carbonyl group of PLP, MRC is
the secondary amine obtained upon reduction of
the unstable intermediate Schi¡ base, and k are the
rate constants for each hemireaction. As demon-
strated later, it can be assumed that the ¢rst hemi-
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reaction is extremely rapid in both directions, where-
as the ¢rst order interconversion of MRS-PLP and
the covalent complex MRC-PLP is slow. Due to the
stability of this covalent complex, k32 is considered
to be negligible with respect to the other rate con-
stants. Therefore, an overall apparent rate constant
of inhibition, Ki, should be proportional to the
(k1Uk2)/k31 ratio.
Fig. 1A depicts the time courses of inhibition of
[3H]ALDO binding after pretreatment of cytosol at
0‡C with PLP in the concentration range of 0.5^20
mM for various periods of time. In order to deter-
mine if any inactivation of the MR can be ascribed
to the conditions of the reaction rather than the re-
activity with PLP, controls were treated without the
addition of PLP (0 mM). As can be seen, the inhibi-
tion of steroid binding was time- and PLP concen-
tration-dependent. The reaction followed a pseudo-
¢rst order kinetics during the ¢rst 6 min of incuba-
tion, and the maximal inhibitory e¡ect was reached
at 10 mM PLP. This is more clearly seen in the graph
depicted in Fig. 1B where the initial rate of inactiva-
tion of MR (a condition where the back reaction is
not signi¢cant) was plotted against the concentration
of inhibitor. The function shows a plateau at concen-
trations of inhibitor higher than 10 mM. This satu-
rating e¡ect is consistent with the properties of an
a⁄nity label and suggests that PLP inhibition of the
MR binding capacity probably occurs through bind-
ing to speci¢c sites.
The inset in Fig. 1B depicts a double-reciprocal
plot, from which a k2 value equal to 0.044 þ 0.001
min31 mM31 was calculated from the slope. Because
the double-reciprocal plot is linearly related to the
concentration of reagent, no reversible complex
should be formed prior to the inactivation process,
therefore the k32 value should be indeed negligible as
compared to k2, k31, and k1.
To test the speci¢city of reaction with PLP, chemi-
cally related derivatives of PLP such as pyridoxine,
pyridoxal, pyridoxamine, and pyridoxamine 5P-phos-
phate were assayed at a concentration of 10 mM,
and no signi¢cant inhibitory e¡ect on the MR bind-
ing capacity was observed (data not shown). In order
to con¢rm that the inhibitory e¡ect of PLP occurs
via reversible imine bond formation, we attempted to
reverse the reaction. Therefore, renal cytosol was ¢rst
incubated with 3 mM PLP. The reaction mixture was
Fig. 1. Kinetics of PLP inhibition of renal MR. (A) Inhibition
of ALDO binding to MR by PLP is concentration- and time-
dependent. Renal cytosol in PEGM bu¡er was preincubated at
0‡C with PLP at a ¢nal concentration ranging from 0.5 mM to
20 mM. At the indicated times, aliquots of 0.5 ml were re-
moved and reduced by adding 8.3 Wl of 0.6 M NaBH4. When
the reaction was exhausted, the treatment with NaBH4 was re-
peated. The excess of reagent was cleared by a quick centrifuga-
tion over a Sephadex G-25 minicolumn. Controls were treated
as the samples but without the addition of PLP (0 mM). The
medium was supplemented with 2 mM dithiothreitol, 100 nM
RU28362, and 20 nM [3H]ALDO ( þ 500-fold radioinert
ALDO) then incubated at 0‡C for 4 h. Bound steroid was sepa-
rated from free with charcoal/dextran, and the remaining specif-
ic binding was plotted against the preincubation time with PLP.
(B) The inactivation of the MR by PLP follows saturable pseu-
do-¢rst order kinetics. The apparent rate constants of inhibi-
tion, Ki, were calculated from the graphics shown in A and
plotted as a function of the PLP concentration. The insert de-
picts a double-reciprocal plot. (C) Inactivation of MR by treat-
ment with PLP is reversible. Kidney cytosol was incubated with
3 mM PLP for 8 min at 0‡C. The samples were cleared of ex-
cess reagent by a quick centrifugation over Sephadex G-25 min-
icolumns. The eluates were divided into two equal fractions.
One half was ¢rst reduced with NaBH4 and then treated with
60 mM of primary amines (white symbols) and the other half
was ¢rst treated with the amines and then reduced (black sym-
bols). Aliquots were removed at di¡erent times, cleared by gel
¢ltration, and the [3H]ALDO binding capacity was measured.
Symbols represent the following treatments: (F) no treatment;
(a) reversion by L-Lys, (O) NK-acetyl-Lys or (E) NO-acetyl-Lys
followed by reduction with NaBH4 ; reduction with NaBH4 fol-
lowed by incubation with (b) L-lysine or (R) NK-acetyl-Lys.
(D) PLP inhibition of native MR is pH-dependent. Kidney cy-
tosol was treated with 3 mM PLP (as shown in A) in bu¡er ad-
justed to the indicated pH. Binding of [3H]ALDO (b) or
[3H]CORT (a) was measured and the Ki was then plotted
against the pH of the reaction.
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immediately loaded onto a Sephadex G-25 minicol-
umn and centrifuged quickly to remove the excess of
reagent. Samples were then split in half, one half
was ¢rst reduced with NaBH4 and then treated
with a 60 mM excess of primary amines, and the
other half was treated ¢rst with the amines and
then reduced. Aliquots were removed from the reac-
tion at di¡erent times, cleared by a quick gel ¢ltra-
tion, and steroid binding was assayed. Results are
shown in Fig. 1C.
The addition of the primary amines L-lysine and
NK-acetyl-lysine prior to reduction with NaBH4 re-
sulted in reversal of the inhibition, whereas NO-ace-
tyl-lysine was incapable of reversing the reaction. On
the other hand, the addition of amines after reduc-
tion with NaBH4 failed to reverse the inhibitory ef-
fect of PLP. Therefore, it is likely that the inhibition
of the steroid binding capacity is a consequence of
reversible imine bond formation on the MR. Inas-
much as the reactivities of L-Lys and NK-acetyl-Lys
are similar, it is also likely that under these experi-
mental conditions the O-amino group of lysine is
the reactive species rather than K-amino groups.
This is more clearly inferred from the inability of
NO-acetyl-lysine to reverse the reaction. A k31 value
equal to 0.21 þ 0.03 min31 mM31 was measured for
the reversion reaction shown in Fig. 1C, therefore a
similar k1 value (0.20 min31 mM31) could be calcu-
lated.
Since the reaction of PLP proceeds by nucleophilic
attack of the carbonyl group of its aldehyde moiety
on amino groups to yield a Schi¡ base [35], an in-
crease of the Ki at higher pH values due to the de-
protonation of the O-amino group is expected. Fig.
1D, however, shows an unexpected function for this
relationship. In e¡ect, the Ki value increased as a
function of the pH, but it reached a plateau between
pH 7.4 and 8.5 and is dramatically decreased at pH
9.0. This pH is close to the pKa value of O-amino
groups and should be expected to exhibit maximum
deprotonation and reactivity with PLP. It should be
noted that not only the inhibition rate constant, but
also the maximum ALDO binding capacity of the
MR dramatically decreased at pH 9.0. When
[3H]CORT was used as ligand, similar results to
those observed with ALDO were also obtained, dem-
onstrating the independence of this reaction with the
agonist.
3.2. Stabilisation of the MR^hsp90 association by
cross-linking
It is known that the multimeric structure of a ste-
roid receptor in tight association with hsp90 is a sine
qua non requirement for steroid binding. This is
more evident for MR, GR and progesterone receptor
than for oestrogen receptor, although it has been
clearly demonstrated that hsp90 is also essential for
optimal oestradiol binding to the oestrogen receptor
[36]. The physiological signal for the dissociation of
hsp90 from the MR is the binding of steroid, but
transformation can be arti¢cially generated in vitro
in the absence of hormone, e.g. high ionic strength or
at extreme pH [2]. Because we utilised bu¡ers at high
alkaline pH, the latter can be the case to explain why
the Ki decreases at a pH s 8.0. Therefore, we cross-
linked the MR to the endogenous hsp90-based chap-
erone system to stabilise its oligomeric structure. The
hydrodynamic pro¢le of cross-linked products was
analysed by ultracentrifugation over a sucrose gra-
dient.
Fig. 2A shows the sedimentation pro¢les of [3H]-
ALDO^MR native complexes at various pH values.
The native ALDO/MR complex shows a major peak
at 9.3 S (untransformed receptor) and a minor peak
at 5.0 S (transformed receptor) at pH 7.4. Alkalin-
isation of the medium increased the transformation
of the MR, so a lower 9.3 S/5.0 S ratio was consis-
tently obtained at pH 8.5 and pH 9.5. This observa-
tion justi¢es both the decrease of the total steroid
binding capacity of the MR and the decreased inhi-
bition rate constant obtained when the maximum
deprotonation of the O-amino group occurs. We con-
¢rmed that hsp90 is present in the 9.3 S, untrans-
formed form, by shifting the 9.3 S peak to 11.4 S by
preincubating samples with the anti-hsp90 3G3 anti-
body. On the other hand, the 5.0 S peak underwent
no shift under the same experimental conditions, in-
dicating that the hsp90 complex is dissociated from
MR in the 5.3 S form.
Fig. 2B depicts the sedimentation pro¢les for
cross-linked MR. When the pH was 9.5, the MR
was recovered in the untransformed form. This fully
conserved form of MR was also obtained in a high
ionic strength bu¡er containing 0.5 M KCl, a con-
dition which transforms the native receptor. When
cross-linked MR was incubated with the anti-hsp90
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antibody, a shift to the 11.4 S form was also ob-
tained. These results demonstrate that hsp90 was co-
valently and stably associated to the MR regardless
of the pH or ionic strength of the medium.
We next con¢rmed the inhibitory e¡ect of PLP on
steroid binding using cross-linked MR. The inactiva-
tion curves by PLP were indistinguishable from those
obtained in Fig. 1 with native MR. Fig. 2C depicts
the variation of the Ki with the pH for cross-linked
MR. The pH dependence for the inactivation of MR
correlates well with a theoretical curve calculated
from the equation:
K i  kmax1 H=Ka 2
As can be seen, the inactivation rate increases with
the pH and reaches a plateau at pH v9.0. This is
consistent with optimal reactivity of deprotonated O-
amino groups at a pH that approaches the pKa of a
lysine O-amino group. In e¡ect, from the intercept
and slope of a plot of 1/Ki vs. [H], we calculated
a kmax of 0.51 min31 (the pH-independent value) and
a pKa of 9.4, a value that is expected for the O-amino
of a lysine group. We therefore conclude that lysine
O-amino groups are modi¢ed by PLP. In addition,
since we worked with cross-linked MR, the results
argue against the possibility that the receptor inacti-
vation by PLP observed in Fig. 1 could have been
generated by the dissociation of hsp90.
3.3. Aminoalkylation of the MR by TNBS
In order to con¢rm that the previously described
inactivation of MR from kidney cytosol is due to
modi¢cation of O-amino groups, we used TNBS, an-
other speci¢c aminoalkylating agent [34], to modify
cross-linked MR in collecting duct cell cytosol. As
Fig. 2. Stabilisation of the MR oligomeric complex. (A) Hydrodynamic pro¢les of native MR. Kidney cytosol in PEG bu¡er was la-
belled with [3H]ALDO for 4 h at 0‡C. After adsorbing free steroid, the [3H]steroid/MR complexes were resolved on a 5^20% sucrose
gradient. Fractions were collected by gravity £ow and the radioactivity counted. Conditions are: b, native MR at pH 7.4; a, native
MR incubated with 3G3 anti-hsp90 antibody before centrifugation; F, native MR at pH 8.5; O, native MR at pH 9.5. (B) Hydrody-
namic pro¢les of cross-linked MR. Dimethyl pimelimidate cross-linked MR was labelled with [3H]ALDO as described for A and cen-
trifuged on a sucrose gradient. For comparative purposes, the elution pro¢le of native MR disassembled by treatment with high ionic
strength bu¡er is also shown. Conditions are: F, cross-linked MR at pH 7.4; E, cross-linked MR preincubated with 3G3 anti-hsp90
antibody before centrifugation; a, cross-linked MR at pH 9.5; O, cross-linked MR in bu¡er containing 0.5 M KCl; b, native MR
in bu¡er containing 0.5 M KCl. (C) pH dependence for PLP inhibition of cross-linked MR. Cross-linked MR from kidney cytosol
was treated with 3 mM PLP at several pH values. The Ki was plotted against the pH of the reaction.
Fig. 3. Kinetics of TNBS inhibition on cross-linked MR from
collecting duct cell cytosol. (A) TNBS-dependent inhibition of
steroid binding. Dimethyl pimelimidate cross-linked cytosol
from duct cells was preincubated for the indicated times at 0‡C
with TNBS. The [3H]ALDO binding capacity was measured
after reduction of the alkylated complex with NaBH4. (B) Pseu-
do-¢rst order kinetics of TNBS-dependent inhibition. The resid-
ual binding was plotted against the TNBS concentration. The
inset shows the variation of Ki as a function of the concentra-
tion of the reagent.
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shown in Fig. 3A, the treatment with TNBS also
abolished ALDO binding in a time- and concentra-
tion-dependent fashion. Moreover, the extent of in-
hibition with TNBS is equivalent to that obtained in
Fig. 1A for equivalent concentrations of PLP. Fig.
3B depicts the TNBS concentration-dependent curve.
Consistent with a pseudo-¢rst order reaction (Fig.
3B, inset), a value equal to 0.051 min31 mM31 was
calculated for k2. Therefore, this rate constant of
inactivation is similar to the k2 measured for treat-
ments with PLP (Fig. 1B).
3.4. Modi¢cation of amino groups of the MR does not
a¡ect the Kd for ALDO
To determine whether or not the modi¢cation of
MR lysyl groups a¡ects the total number of binding
sites and/or the a⁄nity of MR for the steroid, we
treated native MR from duct cell cytosol with either
3 mM PLP or 3 mM TNBS, and after stabilising the
aminoalkylated complex, we performed Scatchard
plots using [3H]ALDO, [3H]CORT or [14C]DOC as
tracers. All the steroids showed identical results, so
only the plots obtained with [3H]ALDO are depicted
in Fig. 4A. As can be seen, the Kd for untreated MR
(0.64 þ 0.12 nM) was not di¡erent from the Kd mea-
sured for PLP-treated MR (0.53 þ 0.04 nM) or
TNBS-treated MR (0.50 þ 0.03 nM). However, the
concentration of binding sites was about one-third
lower for modi¢ed receptor than for untreated MR.
It can be entirely possible that the alkylation of
any amino group in the chaperone protein can ac-
count for the loss of steroid binding capacity rather
than a modi¢cation on the receptor itself. To study
this possibility, we ¢rst treated duct cell cytosol with
PLP followed by reduction with NaBH4. Controls
were treated in a similar form but without the addi-
tion of PLP. Then, the modi¢ed MR was immunoad-
sorbed and the hsp90-based chaperone heterocom-
plex was stripped o¡ the receptor with 0.5 M KCl.
The oligomeric structure of the MR with hsp90 was
¢nally reassembled by reconstitution with rabbit re-
ticulocyte lysate and an ATP regenerating system.
The binding of [3H]ALDO was measured as a quan-
titative parameter for the refolding reaction (Fig. 4B,
bar graphs), and the association of hsp90 to the MR
was visualised by Western blot analysis (shown be-
low the bar graph).
Fig. 4. Aminoalkylation of MR does not a¡ect the Kd for
ALDO nor the dynamic association with hsp90. (A) Scatchard
analysis for PLP- and TNBS-treated MR. Cross-linked MR
from duct cell cytosol was treated with 3 mM PLP (a) or 3 mM
TNBS (R), or underwent the same treatment as the reaction
with the alkylating compound, but without adding reagent to
the medium (b). A Scatchard plot was performed using
[3H]ALDO as tracer. (B) Association of hsp90 to the MR. Na-
tive duct cell cytosol treated (+PLP) or not (3PLP) with PLP
was immunoadsorbed and stripped by high ionic strength where
indicated. The [3H]ALDO binding capacity (bar graph) and the
association with hsp90 (Western blots shown below each bar)
were evaluated before and after the treatment with PLP. Condi-
tions are: (1) non-immune pellet ; (2) immune pellet ; (3) im-
mune pellet stripped with 0.5 M KCl; (4) the stripped immune
pellet reconstituted with rabbit reticulocyte lysate; (5) cytosol
was treated with 3 mM PLP for 6 min at 0‡C and, following
reductive stabilisation of the product, the modi¢ed MR was im-
munoprecipitated; (6) the immune pellet of PLP-modi¢ed MR
was stripped with 0.5 M KCl; (7) hsp90-free unmodi¢ed MR
immune pellet was incubated with 3 mM PLP for 6 min at 0‡C
and, after reductive stabilisation of the product, the heterocom-
plex was reconstituted with rabbit reticulocyte lysate; (8) hsp90-
free unmodi¢ed MR immune pellet was ¢rst incubated with
3 mM PLP for 6 min at 0‡C, and then incubated with 60 mM
L-Lys for 30 min before reduction with NaBH4 followed by
reconstitution with rabbit reticulocyte lysate.
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The association of hsp90 with unmodi¢ed MR was
lost, and also the steroid binding, by incubating the
co-immunoprecipitated MR^hsp90 complex with 0.5
M KCl (condition 3 vs. condition 2). Reconstituting
the oligomeric complex restored 80% of the ALDO
binding capacity of MR (condition 4). On the other
hand, when the MR was treated with PLP and im-
munoprecipitated, the ALDO binding capacity was
only 30% (condition 5) of that measured in the un-
modi¢ed MR (condition 2). It is important to em-
phasise that hsp90 was recovered in this immune
pellet of PLP-treated MR. The association of hsp90
with MR was lost by treatment with high ionic
strength and, consequently, the steroid binding ca-
pacity was fully abolished (condition 6). Condition
7 represents immunoprecipitated native receptor that
was stripped of associated proteins followed by treat-
ment with PLP. After alkylation of the hsp90-free
MR, its oligomeric complex was reconstituted by in-
cubation with reticulocyte lysate. The binding ca-
pacity for ALDO was restored to 80% of the level
of PLP-modi¢ed MR shown in condition 5. Impor-
tantly, this result and the Western blot analysis
clearly demonstrate that the alkylated MR fully pre-
served its capability to reassociate with hsp90 after
alkylation, which is a direct evidence that the PLP-
modi¢ed MR is not e¡ected in its dynamic equilibri-
um with the proteins of the hsp90 heterocomplex.
Finally, when the unstable Schi¡ base generated
by reaction of PLP with the stripped MR was re-
versed by incubation with an excess of L-lysine prior
to the reaction with NaBH4 (condition 8), full recon-
stitution of the MR^hsp90 heterocomplex was
achieved (compare with condition 4), indicating
that the chemical treatment did not a¡ect per se
the capability of the MR to interact with hsp90.
3.5. Determination of the number of amino groups
involved in the inactivation of the MR by
alkylating agents
The stoichiometry for MR alkylation was deter-
mined for PLP-treated or TNBS-treated MR immu-
noprecipitated from duct cell cytosol. The immune
pellet was divided into two fractions. After stripping
o¡ the hsp90 complex from one of the fractions, the
MR associated to the Sepharose pellet was extracted
and the number of reactive lysines was quanti¢ed by
spectrophotometry. The other fraction was used to
measure the [3H]ALDO binding capacity. Inasmuch
as one molecule of ALDO binds to one molecule of
MR, we therefore calculated the number of reactive
lysines per molecule of receptor. The results are
shown in Fig. 5A.
The plots obtained with both reagents are similar
and do not follow a linear function. This indicates
that not all of the amino residues are modi¢ed at the
same rate which, in turn, can be determined by the
accessibility of such residues to the reagent. The ex-
trapolation of the linear phase of the plot to zero
binding capacity shows an average stoichiometry
equal to 1.15 þ 0.18 lysine per molecule of MR. In
other words, it appears that modi¢cation of only one
residue accounts for 70% of the total inhibition of
ALDO binding capacity to MR.
In order to determine whether the presence of li-
gand can prevent the modi¢cation of this Lys group,
Fig. 5. Aminoalkylation by PLP or TNBS of a sole lysine resi-
due is impeded by occupancy of the ligand binding pocket of
the MR. (A) Number of Lys modi¢ed per molecule of receptor.
Native MR immunopellet from duct cell cytosol was divided
into two fractions. One fraction was used to measure the
[3H]ALDO binding capacity to determine the number of MR
molecules in the immune pellet. The other fraction was treated
with several concentrations of either PLP (a) or TNBS (b),
and the number of reactive lysines was determined by spectro-
photometry of the products as described in Section 2. The plot
depicts the fraction of remaining bound steroid (Bo) with re-
spect to untreated MR (B) versus the number of modi¢ed Lys
per molecule of MR. (B) Protective e¡ect of ALDO on inacti-
vation by aminoalkylation. Immunopuri¢ed cross-linked MR
from duct cell cytosol was incubated for 4 h at 0‡C with 20
nM ALDO followed by alkylation with 3 mM PLP or 3 mM
TNBS for 6 min at 0‡C. After stabilising the product by reduc-
tion with NaBH4, the bound steroid was dissociated by an in-
cubation at 37‡C for 1 h. The released ALDO was washed out
and the immune pellet was reincubated with 20 nM [3H]ALDO
to measure the steroid binding capacity. Conditions are: (1) im-
mune pellet of untreated MR; (2) immune pellet of PLP-treated
MR; (3) immune pellet of PLP-treated MR preincubated with
ALDO; (4) immune pellet of TNBS-treated MR; (5) immune
pellet of TNBS-treated MR preincubated with ALDO.
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we preincubated cross-linked MR with an excess of
ALDO and then carried out the reaction with either
PLP or TNBS. Fig. 5B clearly shows that the pres-
ence of ALDO in the steroid binding pocket prevents
the inactivation by both alkylating reagents (bars 3
and 5) as compared to the respective control incuba-
tions performed with unliganded MR (bars 2 and 4).
Although this ligand protection is not conclusive, it
suggests that the amino group involved in the reac-
tion with PLP or TNBS might lie in or near the
steroid binding pocket of the MR. On the other
hand, it may well re£ect a di¡erential protrusion of
a speci¢c reactive amino group upon steroid binding.
3.6. Mineralocorticoid features of synthetic and
natural ligands
It is classically accepted that C21-hydroxylation
enhances the mineralocorticoid properties of steroid
ligands. A typical example of this requirement is the
weak activity exhibited by PROG as compared to its
21-hydroxy derivative, DOC. However, we have
postulated [27,31,37] that the mineralocorticoid e¡ect
of a given steroid is mainly due to its planar confor-
mation rather than the functional groups present in
the molecule. Thus, the biological properties of the
£at synthetic 21-deoxysteroid 11-OP were compared
to those exhibited by natural agonists.
Fig. 6A depicts the competition curves between
unlabelled steroid and [3H]ALDO. The relative a⁄n-
ity obtained for each steroid is (EC50 values in nM
are given in parentheses): ALDO (2.3 þ 0.3) = DOC
(2.8 þ 0.6) = CORT (3.1 þ 0.6)s SC9420-spironolac-
tone (SPO) (9.1 þ 3.5) = PROG (15.1 þ 7)s 11-OP
(43.2 þ 3.0)E6-OP and testosterone (T = O) (no sig-
ni¢cant binding). Fig. 6B depicts the dose^response
curves for the steroids as urinary Na/K ratio. Due
to the combined protective action of several factors
such as the activity of 11L-hydroxysteroid dehydro-
genase [10], binding to transcortin and other plasma
proteins [38], and/or the putative selectivity of the
MR itself [39], the in vivo biological e¡ect of
CORT is impaired in spite of its high a⁄nity for
MR in the absence of those regulatory factors, as it
is well known. Interestingly, the a⁄nity of 11-OP is
about 20-fold lower than the a⁄nity of DOC for the
MR, but the in vivo e¡ect of 11-OP is as potent as
that exhibited by DOC at low doses and even ap-
proaches that of ALDO at doses v10 Wg. These ob-
servations con¢rm our previous reports [27,31]. On
the other hand, the antagonist steroids PROG and
SPO, and the inactive steroids 6-OP and testosterone
Fig. 6. Mineralocorticoid properties of the ligands. (A) Steroid competition curves for binding to MR. Kidney cytosol in PEGM bu¡-
er containing 2 mM dithiothreitol and 1 WM RU486 was incubated with 5 nM [3H]ALDO ( þ 10 WM non-radioactive ALDO) and in-
creasing concentrations of the indicated steroids. After 12 h at 0‡C, bound steroid was separated from free with charcoal/dextran, and
the speci¢cally bound radioactivity was plotted against the relative concentration of competitor. Competitor ligands are: b, ALDO:
a, DOC; E, SPO; R, CORT; P, PROG; F, 11-OP; O, 6-OP; S, T = O. (B) Mineralocorticoid e¡ect. Steroids were injected into
adrenalectomised male rats and the natriuresis decrease and kaliuretic increase were measured in urine. Values of Na/K ratio repre-
sent the mean þ S.E.M. of six animals per dose. (C) 11-OP potentiates ALDO mineralocorticoid e¡ect. The mineralocorticoid biologi-
cal e¡ect of a suboptimal dose of 0.06 Wg ALDO (black bars) was measured by co-injecting either vehicle (EtOH), 100 Wg SPO, 100
Wg PROG, 0.6 ng 11-OP, or 100 ng 6-OP. Dotted bars represent the Na/K ratio for control values obtained by injecting the steroid
(or EtOH) without co-injecting ALDO. Data are the mean þ S.E.M. of eight animals per group. The following co-treatments with
ALDO are statistically di¡erent from the control co-injected with EtOH: SPO at P6 0.003, PROG at P6 0.010, and 11-OP at
P6 0.001.
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are very weak mineralocorticoids, if they are not to-
tally inactive. It is interesting to emphasise that the
maximum activity of 11-OP in transcription assays is
as e⁄cient as that measured for ALDO, CORT, cor-
tisol and DOC (data not shown).
The bar graph in Fig. 6C shows that V40% of the
maximum mineralocorticoid e¡ect can be measured
using a suboptimal dose of 0.06 Wg of ALDO. As
expected, this e¡ect was totally abolished by co-treat-
ment with SPO and partially inhibited by co-treat-
ment with PROG. Importantly, as low a dose of 11-
OP as 0.6 ng, which is per se ine¡ective to promote
any biological e¡ect, potentiated the e¡ect of 0.06 Wg
of ALDO, so that the maximal mineralocorticoid
e¡ect was reached. On the other hand, the inactive
stereoisomer 6-OP does not a¡ect the ALDO-depen-
dent response.
These results can be due to several reasons, but
more likely because 11-OP binds to a putative second
binding site on the MR di¡erent from the ALDO
binding site, or because the binding of 11-OP induces
a di¡erent conformational change on the MR with
respect to the conformation adopted by the MR
upon ALDO binding.
3.7. The ligand in the steroid binding pocket protects
the MR from the inhibitory e¡ect of PLP
In the experiment shown in Fig. 5B we demon-
strated that preincubation of MR with ALDO pre-
vents the inactivating e¡ect of PLP. Therefore, we
addressed the question whether this protective action
of the steroid is a common feature for all MR li-
gands. Thus, we ¢rst treated duct cell cytosol with
the cross-linking agent dimethyl pimelimidate, and
then isolated the MR oligomeric complex by immu-
noprecipitation. The immune pellet was incubated
with steroid for 4 h at 0‡C in PEGM bu¡er at pH
7.4, and the free ligand was washed out. This ligand-
occupied MR pellet was treated with 3 mM PLP for
6 min. After the reductive stabilisation of the Schi¡
base, the samples were incubated at 37‡C for 1 h to
dissociate bound steroid. Consistent with a previous
work [27], control experiments demonstrated that
there is no change in the steroid binding capacity
of cross-linked MR after this incubation. Therefore,
after washing the immune pellets, a reincubation
with [3H]ALDO for 4 h at 0‡C was performed and
the speci¢c [3H]ALDO binding capacity was mea-
sured.
Fig. 7A shows that the steroid binding capacity of
cross-linked MR preincubated with vehicle (EtOH)
was inhibited by further alkylation with PLP as com-
pared to untreated control. The protective e¡ect of
the ligand on the PLP-dependent inactivation of
cross-linked MR could be evidenced not only for
ALDO, but also for DOC and CORT. On the other
hand, when MR was prebound to the antagonists
PROG and SPO, as well as the inactive ligands
T = O and 6-OP, no protection was evidenced upon
treatment with PLP followed by rebinding of [3H]-
ALDO. Interestingly, the synthetic agonist 11-OP
was also incapable of protecting the MR, demon-
strating that the binding of 11-OP to the MR exhib-
its di¡erent properties with respect to natural ago-
nists. It should be noted that identical results (not
shown) were also obtained with TNBS-treated MR.
Fig. 7B depicts the MR inactivation rate upon
treatment with PLP at di¡erent pH values. As shown
in Fig. 2C for kidney cytosol, the maximal inactiva-
Fig. 7. Di¡erential steroid binding to the MR is evidenced by
receptor alkylation. (A) Protective e¡ect of ligands. Immuno-
puri¢ed cross-linked MR was preincubated with steroid and
then treated with PLP exactly as described for Fig. 5B. Control
represents immunopellets not treated with PLP. EtOH repre-
sents preincubation with vehicle instead of steroid. Results are
the mean þ S.E.M. of three experiments each performed in du-
plicate. (B) pH dependence of PLP inhibition on immunopuri-
¢ed cross-linked MR protected by ligands. Cross-linked MR
was immunoadsorbed from duct cell cytosol and the indicated
steroids were bound to the receptor. Hence, a reaction of the
steroid/receptor complexes with PLP was carried out at various
pH values for short incubation times (as described for Fig. 1A
and 3A) followed by reduction with NaBH4. Steroids were dis-
sociated from the MR by incubating the samples at 37‡C for
1 h. After washing the immune pellets with bu¡er, the [3H]-
ALDO binding capacity was measured. From the slopes of
binding vs. time plots, Ki was calculated and then plotted
versus the pH of the reaction. The MR was bound to: *, un-
liganded MR; S, T = O; O, 6-OP; F, 11-OP; E, SPO;
P, PROG; b, ALDO; a DOC; R, CORT.
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tion of unliganded receptor is reached at pH v9.0,
suggesting the blockade of an O-amino group. Simi-
larly, steroids that do not exhibit binding properties
to the MR such as testosterone and 6-OP were in-
capable of a¡ecting the inactivation rate of the MR
which is indistinguishable from the control. In con-
trast, the physiological agonists ALDO, DOC and
CORT protected the MR from inactivation in the
full range of pH values. Consistent with the notion
that the binding of 11-OP to the MR is not equiv-
alent to the binding of natural agonists, the synthetic
agonist 11-OP shows a similar function as the inac-
tive steroids at pH 98.0, but a partial protective
action at higher pH values. Such an e¡ect is clearly
di¡erent from the observations obtained with both
natural agonists and inactive steroids. Interestingly,
a similar e¡ect as that of 11-OP can be described for
SPO and PROG, antagonistic steroids whose rate
constants of inhibition are not distinguishable from
the Ki obtained with 11-OP in the complete range of
pH values assayed.
Taken together, these results demonstrate that the
binding of natural agonists to the MR is comparable
to neither the binding observed for 11-OP nor the
binding of the antagonists SPO and PROG. Remark-
ably, 11-OP is not an antagonist, but an agonist that
not only possesses mineralocorticoid e¡ects per se
but is also able to potentiate the ALDO biological
e¡ect.
3.8. Analysis of the MR conformation by
limited proteolysis
In view of the peculiar results obtained in Fig. 7B
for 11-OP and the antagonistic ligands, we addressed
the hypothesis that all these steroids can induce a
di¡erential conformational change in the MR as
compared to natural agonists. Therefore, we incu-
bated the MR from cortical collecting duct cytosol
with steroid and then modi¢ed the receptor with
[32P]PLP. The labelled modi¢ed receptor was concen-
trated by immunoprecipitation and digested by lim-
ited proteolysis with K-chymotrypsin for 1 h at 10‡C.
Fig. 8 shows that the treatment of unliganded MR
with [32P]PLP followed by proteolysis with 10 U/ml
of K-chymotrypsin yielded several proteolytic frag-
ments ranging from the size of full-length MR
(V110 kDa) and 95 kDa. In addition, two smaller
fragments of 67 kDa and 34 kDa were also generated
during the limited proteolysis. This pattern was not
a¡ected by binding of steroid.
When the concentration of K-chymotrypsin was
increased 4-fold, full degradation of unliganded
MR was observed. However, the ALDO-bound
MR complex still shows the 34 kDa band as a pre-
dominant intermediate proteolytic product. Similar
results were also obtained with the agonist CORT.
On the other hand, the antagonist PROG was unable
to protect against the degradation of both the full-
length MR and its fragments. These observations
clearly indicate that following agonist binding only
the 34 kDa fragment becomes resistant to K-chymo-
trypsin. This was assigned to a particular conforma-
tion acquired by MR according to the nature of the
bound hormone.
Interestingly, the synthetic agonist 11-OP cannot
be grouped with any of those two classes of ligands.
In e¡ect, the MR that is bound to 11-OP, showed
intermediate pattern degradation upon digestion with
K-chymotrypsin. Thus, V40^50% of the 34 kDa
fragment is still intact as compared to the 80% still
remaining for the ALDO- or CORT-bound MR. On
the other hand, the bent stereoisomer 6-OP is totally
Fig. 8. Limited chymotrypsinisation of steroid/MR complexes.
Cytosol from duct cells was incubated with 1 WM steroid for 4 h
at 0‡C. Samples were then incubated with [32P]PLP (3 mM to-
tal PLP) for 6 min at 0‡C and reduced with NaBH4. The MR
was immunoprecipitated, stripped with PEG/0.5 M KCl bu¡er,
and resuspended in PBS containing K-chymotrypsin from bo-
vine pancreas at the concentrations indicated above the graph.
The digestion was performed for 1 h at 10‡C. The reaction was
stopped by boiling the samples in SDS-loading bu¡er.
[32P]PLP-labelled proteins were resolved by electrophoresis on a
14% SDS^polyacrylamide gel, and visualised by autoradiogra-
phy.
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ine¡ective in protecting the MR from degradation.
We would like to emphasise that both compounds,
11-OP and 6-OP, are 21-deoxysteroids, which share
equivalent functionalities, but exhibit opposite over-
all conformations.
4. Discussion
The rat MR possesses a total of 53 Lys residues,
18 of which are localised in the steroid binding do-
main [40]. This led us to postulate that some lysyl
groups may be essential for the binding of steroid to
the MR. In this work, we provide evidence that this
may be the case due to the substantial inhibition of
hormone binding to MR upon modi¢cation of amino
groups with PLP and TNBS. According to the data
obtained in the experiment shown in Fig. 5, a stoi-
chiometry equal to one Lys residue per molecule of
receptor accounts for about a 70% inhibition of ste-
roid binding. This suggests a critical role for only one
lysyl group in the MR among those 53 total residues.
Regardless of the exact location and number of res-
idues modi¢ed by the treatment of the MR, the im-
portance of this observation is that such inhibition is
prevented if a natural agonist (i.e. ALDO, DOC or
CORT) is bound to the receptor, but it is not pro-
tected upon antagonist binding (i.e. PROG or SPO).
In this sense, the synthetic agonist 11-OP remarkably
resembles the properties of antagonistic compounds
rather than natural agonistic steroids (Fig. 7).
Nevertheless, limited proteolysis of the liganded
MR (Fig. 8) shows that the digestion products ob-
tained depend on the nature of the ligand bound to
the receptor. Thus, controlled proteolysis generated a
key 34 kDa fragment that is totally resistant to deg-
radation only when natural agonists are bound to
MR. Although 11-OP is also a potent agonist its
protective e¡ect is only partial, which strengthens
the notion that 11-OP binding to the MR is not
equivalent to that observed for ALDO. On the other
hand, digestion of PROG/MR or 6-OP/MR com-
plexes showed a similar degradation pattern as the
unliganded MR. This suggests that the induced con-
formational change of the MR upon PROG or 6-OP
binding, if any, is not as dramatic as the structural
change generated by ALDO or CORT. It should also
be pointed out that, in contrast to these ¢ndings with
the MR, antagonists rather than agonists induce pro-
tection of proteolytic fragments for the progesterone
receptor [41], the oestrogen receptor [42] and the ret-
inoic acid receptor [43].
Although the number of lysine groups present in
the protein is high, the saturation curves depicted in
Fig. 1 indicate that only a limited number of residues
can be modi¢ed by the reagent. Actually, the Lys/
MR stoichiometry measured in Fig. 5A demonstrates
that the steroid binding capacity of MR is totally
abolished when three or four lysine groups have
been modi¢ed. Due to the bulky nature of the alky-
lating reagents used in these experiments and the
conditions of the reaction, it is unlikely that these
residues are buried in the receptor structure.
Although our results cannot provide conclusive
evidence as to assign the localisation of the essential
lysine to the ligand binding pocket of the MR, the
di¡erential protective e¡ect obtained with natural
agonists and antagonists leads us to consider that it
is entirely possible that a Lys residue could be lo-
cated in a topological region which is vital for con-
ferring (directly or indirectly) an appropriate envi-
ronment around the steroid binding pocket of the
MR. Interestingly, only full natural agonists exert
e⁄cient protection against inactivation by alkylation.
This is supported by the experiments described in
Fig. 5B and 7. Importantly, the synthetic agonist
11-OP shows discrepancies with natural agonists
both in the protective e¡ect against MR alkylation
and the pattern of proteolytic fragments generated
by limited digestion with K-chymotrypsin.
We have previously postulated that the synthetic
steroid 11-OP may exert its biological e¡ect by bind-
ing to an alternative site on the MR [37]. Other pos-
sible biopharmacological properties that can account
for 11-OP’s biological e¡ect were studied and ruled
out in a previous work [27] (i.e. a longer in vivo half-
life, stronger in vivo binding to renal MR, non-ge-
nomic e¡ects, etc.). In spite of the potent biological
action of 11-OP, its protective e¡ect against inactiva-
tion by PLP at high pH is just partial and closer to
that observed with PROG and SPO (Fig. 7B). Again,
this supports the notion that only agonists bound to
the ALDO binding pocket with an appropriate ori-
entation of the molecule are capable of fully protect-
ing the amino group(s) from alkylating agents. A
reasonable explanation for the di¡erential protective
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e¡ect observed with di¡erent ligands is the putative
di¡erential orientation of the ligand in the steroid
binding pocket or its binding to a completely di¡er-
ent binding site. Accordingly, a recent publication by
Geller et al. [44] described cases of hypertension and
pregnancy-related hypertension by a substitution of
Leu810 by Ser in the hMR. This substitution alters
receptor speci¢city, where PROG, SPO and other 21-
deoxysteroids become mineralocorticoids. Moreover,
Auzou et al. [45] have reported that a mutant of
hMR in Ala773 also confers 11L-substituted spirolac-
tones agonistic properties. Both mutations, Leu810
and Ala773, are localised in the hormone binding do-
main of the MR.
In this work, we also present evidence that a par-
tial agonist/antagonist like PROG and an antagonist
like SPO were incapable of protecting the MR at
physiological pH, and only a partially protective ef-
fect was detected at alkaline pH for both com-
pounds. The actual mechanism of action for SPO is
still controversial. It was initially thought that SPO
competitively inhibits ALDO binding to the MR and
prevents its translocation to the nucleus [46]. How-
ever, it was shown that SPO translocates into the
nucleus associated to MR [47] and can bind to the
DNA in vitro [48]. Both processes seem to be less
e⁄cient than for ALDO. Recently, a cell-dependent
partial agonistic activity of SPO was also reported
[49]. One possible explanation for these features
may also be found in a di¡erential positioning of
SPO in the MR. Our results may be explained by a
similar argument. In e¡ect, even when SPO was
present at saturating concentrations, only a minimal
protective e¡ect against the treatment with PLP
could be evidenced, suggesting that the steroid can
be placed in the ligand binding pocket, but has a
di¡erent orientation of the steroid frame and/or
functional groups. Therefore, modi¢ed lysyl groups
required for ALDO binding remain exposed and,
consequently, unprotected.
An interesting property is that the steroid place-
ment in the ligand binding site of the MR is mainly
due to the overall ligand planarity and/or the ligand’s
ability to adapt its molecule to a very narrow inter-
acting site in the protein, so the C3 = O group of the
steroid A-ring can be anchored to the protein [31,37].
In contrast, the C11 and C19 groups of the steroid
should be interacting with a more spacious area
within the hormone binding domain as judged by
the capacity of bulky ligands to bind to the MR.
Therefore, one can envisage that an all or nothing
event upon hormone binding should be unlikely in
view of the fact that the hormone binding is an adap-
tive process where the whole structure of the protein
changes upon steroid binding. Thus, agonists and
antagonists can overlap their respective orientations
in the binding site, although the ligand-dependent
rearrangement of the MR conformation may be dif-
ferent. For example, it is possible that PROG can
bind to the MR at the same site as ALDO. However,
the total length of the PROG (11.31 Aî for O3^O21)
molecule is not enough as to properly fold the pro-
tein as compared to ALDO (12.45 Aî ). This incon-
venience can be solved by hydroxylation of C21, so
that DOC (12.30 Aî ) acquires potent biological activ-
ity. The acquisition of mineralocorticoid biological
activity by DOC may be the consequence of a
more e⁄cient interaction of the steroid with the helix
H11 of rat MR by anchoring the steroid’s C21-hy-
droxyl group to the Cys939 (or Cys948 of hMR). Ac-
cordingly, similar arguments can explain the miner-
alocorticoid e¡ect of CORT (12.24 Aî ) if the other
environmental regulating factors (i.e. sequestering
proteins, metabolising enzymes, etc.) would not in-
terfere with binding to MR in epithelia and vascular
smooth muscle cells. It is worth underlining that,
although cortisol dissociates more rapidly from the
MR than ALDO [24], it also antagonises ALDO in
non-epithelial tissues.
On the other hand, 11-OP ful¢ls the requirement
for optimal planarity and strongly conserves its con-
formation due to the presence of an extra ether ring,
which confers an extreme rigidity to the molecule.
This rigidity is also shared by the natural agonist
ALDO, a steroid that also exhibits an extra stabilis-
ing ring on the L face of the molecule, although this
extra ring in ALDO opens reversibly under physio-
logical conditions, a property that is not exhibited by
11-OP. Although 11-OP is a £at steroid which does
behave as a potent mineralocorticoid, the length the
molecule is shorter (11.38 Aî ) than the average length
of natural agonists. Inasmuch as the molecular frame
of 11-OP is rigid and stable, it is possible that a
di¡erent orientation of the ligand is required to ¢t
in the ALDO binding site. This ‘enforced’ position-
ing of 11-OP may induce a particular conformational
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change of the MR, which can be evidenced by partial
proteolysis with K-chymotrypsin. On the other hand,
due to the fact that 11-OP potentiates the biological
e¡ect of suboptimal doses of ALDO, it can also be
speculated that the binding of this synthetic steroid
to the receptor does not occur exactly in the same
site where the natural agonists bind to the MR. Such
a putative site can function as a stabiliser of the
active conformation of the MR. This hypothesis is
inferred from the experiments shown in this work as
well as from previously published experiments [27] in
which we showed that inactive concentrations of 11-
OP increased the a⁄nity of ALDO for the MR,
whereas higher concentrations of 11-OP (capable of
competing with ALDO by binding to the ligand
binding site of the MR) exhibited a competitive in-
hibitory e¡ect on ALDO binding. Moreover, the o¡-
rate of ALDO is 3 times lower in the presence of
concentrations of 11-OP that fail to compete with
ALDO [27]. Interestingly, the 21-hydroxylated deriv-
ative of 11-OP has a similar length (12.23 Aî ) as the
length of natural agonists, but it exhibits very weak
mineralocorticoid e¡ect and low a⁄nity for the MR
(unpublished results). This unexpected observation
agrees with the notion that 11-OP (and possibly its
21-hydroxy derivative) binds to a di¡erent binding
site than ALDO, DOC and CORT.
Finally, the di¡erential binding properties of sev-
eral ligands evidenced by the existence of a crucial
amino group in the MR can open new perspectives
on our understanding of steroid^receptor interac-
tions and further activation of this transcription fac-
tor. The use of the sole MR synthetic agonist to date,
11-OP, can also be extremely useful to unravel the
still controversial and poorly understood structural
and functional regulation of the MR.
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